CRISPR Therapeutics AG
CRSP
Rang in Aktien
#3576
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering... CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
Aktienkurs
$49.61
Marktkapitalisierung
$4.80B
Veränderung (1 Tag)
-0.87%
Veränderung (1 Jahr)
-32.94%
Land
CH
Handel CRISPR Therapeutics AG (CRSP)
Kategorie
Healthcare
Gewinn für CRISPR Therapeutics AG (CRSP)
Gewinn im Jun 2026 TTM: $-448.11M
Laut den aktuellen Finanzberichten von CRISPR Therapeutics AG betragen die aktuellen Gewinne des Unternehmens $-448.11M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $-362.67M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2023, der $-150.72M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von CRISPR Therapeutics AG von 2014 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $-448.11M | -22.47% |
| 2025 | $-577.97M | 59.37% |
| 2024 | $-362.67M | 140.62% |
| 2023 | $-150.72M | -76.83% |
| 2022 | $-650.50M | -271.40% |
| 2021 | $379.53M | -209.04% |
| 2020 | $-348.06M | -617.12% |
| 2019 | $67.31M | -140.93% |
| 2018 | $-164.43M | 146.86% |
| 2017 | $-66.61M | 193.19% |
| 2016 | $-22.72M | -12.02% |
| 2015 | $-25.82M | 276.23% |
| 2014 | $-6.86M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | -1,277.15% |
US
|
|
| $-3.09B | 588.90% |
US
|
|
| $-4.02B | 796.26% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -535.31% |
NL
|
